An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers
Article 2016 en
Authors
GB
Giulia Bottai
CR
Carlotta Raschioni
AL
Agnese Losurdo
Abstract
1 min read
Overall, our data indicate that the evaluation of stromal TILs remains the most reliable immune prognostic marker in TNBC, and support the clinical evaluation of anti-PD-1/PD-L1 and anti-LAG-3 in a subset of patients with TNBC who have concurrent expression of both checkpoint receptors.
Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen A. Adegoke, Alexander M. Menzies, Inês Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A Scolyer
Rhiannon K. Beckers, Christina Selinger, Ricardo E. Vilain, Jason Madore, James S. Wilmott, Kate Harvey, Anne Holliday, Caroline Cooper, Elizabeth Robbins, David J. Gillett, Catherine Kennedy, Laurence Gluch, Hugh Carmalt, Cindy Mak, Sanjay Warrier, Harriet E. Gee, Charles Chan, Anna McLean, Emily Walker, Catriona M. McNeil, Jane Beith, Alexander Swarbrick, Richard A Scolyer, Sandra O’Toole
Tuba N. Gide, Inês Pires da Silva, Camelia Quek, Peter M. Ferguson, Marcel Batten, Ping Shang, Tasnia Ahmed, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Richard A Scolyer, Georgina V. Long, James S. Wilmott
Daniel Ortega-Álvarez, David Tébar-García, Marta Casado-Peláez, David Olivares-Osuna, E Castillo-Agea, J Balibrea-Rull, Rosa Angélica Barbella-Aponte, D Pérez-Parra, Eva Musulen, Cristina Guardia, Elena Vinuesa-Pitarch, Esther Sánchez López, Fátima Postigo-Corrales, Ester Ballana, Anna Martínez‐Cardús, Mireia Margelí Vila, Manel Esteller, Pedro L. Fernández, Ginés Luengo‐Gil, ,
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.